Key result
Sildenafil is an efficacious treatment option for the management of severe pulmonary artery hypertension, particularly in developing countries with limited treatment options.
Why the study?
Does sildenafil improve outcomes in patients with severe pulmonary artery hypertension?
Does sildenafil improve outcomes in patients with severe pulmonary artery hypertension?
Sildenafil is an efficacious and reasonable treatment option for severe pulmonary artery hypertension, particularly in resource-limited settings.
May support sildenafil in resource-limited severe PAH settings; leaves open prospective randomized confirmation of outcomes.
Severe pulmonary hypertension is a debilitating disease with short life expectancy that often affects young people. It is usually idiopathic pulmonary artery hypertension and is characterized by progressive elevation of pulmonary artery pressure and vascular resistance, right ventricular failure and death with a limited median survival time. There is an imbalance in vasoconstrictive and vasodilatory substances. The phosphodiesterase-5 inhibitor sildenafil, a pulmonary and penile vasodilator initially approved for erectile dysfunction, is found to be efficacious in severe pulmonary artery hypertension. There are limited treatment options for the management of pulmonary artery hypertension in developing countries and sildenafil is a reasonable treatment option. This article reviews the relevant clinical data in pulmonary hypertension and the role of sildenafil in its management.
No takes yet. Share an insight, caveat, or question.
TP Singh (2010) conducted a review in pulmonary artery hypertension. sildenafil was evaluated. Sildenafil is an efficacious treatment option for the management of severe pulmonary artery hypertension, particularly in developing countries with limited treatment options.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: